China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) announced that it has received approval in China to conduct a multi-center, randomized, double-blind, placebo-controlled Phase III study of its polypeptide drug candidate RAY1225 in obese and overweight patients.
Drug Profile and Previous Trials
RAY1225 is a long-acting glucagon-like peptide-1 (GLP-1) drug with dual activation activity of the GLP-1 receptor and glucose-dependent insulin-promoting polypeptide (GIP) receptor. It is being developed for blood sugar reduction, weight loss, and metabolic syndrome treatment. Previously, Part A of a Phase II clinical study in obese/overweight patients and type 2 diabetes patients in China met the primary endpoint. The drug was also cleared for a Phase II study in obese/overweight patients in the US last month.
Study Details
The Phase III study will further evaluate the efficacy and safety of RAY1225 in a larger patient population. The drug’s dual-action mechanism is expected to provide significant benefits in weight management and blood sugar control, addressing the growing need for effective therapies in these areas.-Fineline Info & Tech
Leave a Reply